Length of Stay with ACURATE neo vs. Evolut™ R
ACURATE neo Aortic Valve System – Clinical Data
Clinical Highlights
Study Design
Routine use of the ACURATE neo self-expanding valve is
associated with improved procedural outcomes and reduced
post-operative length of stay: Insights from a single-center
registry (ACURATE neo vs. Evolut R)
Kotronias RA, Banning AP, Kharbanda RK. Oxford University
Hospital. Presented at EuroPCR 2019 by R. A. Kotronias.
Single-center study from Oxford, Great Britain, evaluating the
impact of valve selection on procedural outcomes, length of stay
(LoS), and 30-day mortality in 231 patients treated with either
ACURATE neo (n = 143) or Evolut R (n = 88) between March 2017 and
September 2018.
ACURATE neo demonstrates reduced post-operative complications
and permanent pacemaker rates and comparable mortality and stroke
rates vs. Evolut R.
Improvements in procedural outcomes with ACURATE neo are
associated with reductions in post-operative length of stay A
multivariate linear regression model identified peri-procedural
complications, pre-existing RBBB, and new permanent pacemaker
implantation as independent predictors of post-operative length of
stay.
3 3 32 2
In-hospital mortality
30-day mortality
0
Stroke
10
29
8 9
New PPI after TAVI
1 1
Life- threatening
bleeding
Major vascular
complications
ACURATE neo (n = 143) Evolut R (n = 88)
ACURATE neo
0
1
2
3
4
5
6
7
8
9
10
Evolut R
Post-Operative Length of StayProcedural Outcomes
Leng
th o
f sta
y (d
ays)
% o
f pat
ient
s
aOR 0.16 (0.05–0.5)
aOR 0.14 (0.01–0.68)
aOR 0.14 (0.03–0.68)
30
35
20
25
15
10
5
0
www.bostonscientific.eu/ACURATEneo © 2019 Boston Scientific
Corporation or its affiliates. All rights reserved. DINSH0243EA
All trademarks are the property of their respective owners.
CAUTION: The law restricts these devices to sale by or on the
order of a physician. Indications, contraindications, warnings, and
instructions for use can be found in the product labeling supplied
with each device. Information for use only in countries with
applicable health authority product registrations. Not intended for
use or distribution in France, Japan, and the USA. SH-655603-AA
